(THIO)CARBAMOYL-CYCLOHEXANE DERIVATIVES AS D3/D2 RECEPTOR ANTAGONISTS

• Main Authors: VAGO, ISTVAN, KISS, BELA, LASZY, JUDIT, SAGHY, KATALIN, LASZLOVSZKY, ISTVAN, GYERTYAN, ISTVAN, GALAMBOS, JANOS, AGAINE' CSONGOR EVA, NOGRADI, KATALIN
• Format: Patent
• Language: English; Serbian
• Published: 31.10.2013
• Subjects: CHEMISTRY; HETEROCYCLIC COMPOUNDS; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; ORGANIC CHEMISTRY; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

Jedinjenje formule (I):naznačeno time daR1 i R2 nezavisno predstavljaju vodonik, iliC1-6 alkil, sa pravim ili razgranatim lancem izbomo supstituisan sa jednom ili više C1-6 alkoksikarbonil, aril ili (C1-6 alkoksikarbonil)- C1-6 alkil grupa, ili R1 i R2 mogu da formiraju heterocikličan prsten sa susednim atomom azota, koji može biti zasićen ili nezasićen izborno supstituisan monocikličan ili dvocikličan prsten, koji može da sadrži dodatne heteroatome izabrane od O, N ili S, iliC2-7 alkenil sa 1 do 3 dvostuke veze, ilimono-, dvo- ili tricikličan aril izborno supstituisan sa jednom ili više C1-6 alkoksi. trifluoro C1-6 alkoksi, C1-6 alkoksikarbonil, C1-6 alkanoil, aril. C1-6 alkiltio, halogen ili cijano grupa, iliizborno supstituisanu mono-, dvo- ili tricikličnu cikloalkil grupu. iliaroil grupu; X predstavlja atom kiseonika ili sumpora; n je ceo broj od 1 do 2,i/ili geometrijski izomeri i/ili stereoizomeri i/ili diasteremeri i/ili soli i/ili hidrati i/ili solvati tog jedinjenja.Prijava sadrži još 7 patentnih zahteva. The present invention relates to new D3 and D2 dopamine receptor subtype preferring ligands of formula (I): wherein R1 and R2 represent independently a substituent selected from hydrogen, alkyl, aryl, cycloalkyl, aroyl, or R1 and R2 may form a heterocyclic ring with the adjacent nitrogen atom; X represents an oxygen or sulphur atom; n is an integer of from 1 to 2, and/or geometric isomers and/or stereoisomers and/or diastereomers and/or salts and/or hydrates and/or solvates thereof, to the processes for producing the same, to pharmaceutical compositions containing the same and to their use in therapy and/or prevention of a condition which requires modulation of dopamine receptors.